PEPTIDE PHARMACEUTICAL COMPOSITION, MEANS ON ITS BASIS FOR THE TREATMENT OF GASTRODUODENAL DISEASES CAUSED BY HELICOBACTER PYLORI, AND A METHOD OF ITS USE

摘要

The invention relates to medicines based on a peptide pharmaceutical composition for the treatment of gastroduodenal diseases caused by Helicobacter pylori. Technical result: the glutamyl-aspartyl-glycine peptide exhibits a specific activity, which is expressed in the inhibitory effect on the mitochondrial mechanisms of apoptosis in gastric epithelial cells induced by Helicobacter pylori, which inhibits the effect of Helicobacter pylori on cells, and reduces the induction of appoptosis. A pharmaceutical composition is provided having a specific activity, characterized in that the active substance contains an effective amount of a peptide of the formula H-Glu-Asp-Gly-OH and a pharmaceutically acceptable carrier with respect to Helicobacter pylori; the use of a pharmaceutical composition for the manufacture of a medicament for the treatment of gastroduodenal diseases caused by Helicobacter pylori containing, as an active ingredient, an amount of a peptide of the formula H-Glu-Asp-Gly-OH and a pharmaceutically acceptable carrier, effective against Helicobacter pylori; the product contains the active substance in an amount of from 1 to 10 μg / kg and is in a form suitable for oral or parenteral administration; and also a method for treating gastroduodenal diseases caused by Helicobacter pylori by inhibiting apoptosis in gastric epithelial cells induced by Helicobacter pylori, comprising administering to a subject in need thereof an agent containing an amount of a peptide of formula H-Glu-Asp- effective against Helicobacter pylori Gly-OH at a dose of 1 to 10 μg per 1 kg of body weight orally daily 3 times a day for 10-20 days or parenterally once daily for 10 days, while the introduction is carried out orally or parenterally.